Cardiovascular disease (CVD) constitutes one of the world’s prominent health threats, generally leading to unfavorable enduring outcomes. The new molecular and genetic knowledge of CVD is ever-expanding; consequently, this has brought about the innovation of cell and molecular therapies that carry hope for treatment. Advanced approaches have been employed to enhance the effectiveness and the period of these therapies, some of which involve new agents alongside biological ones. Targeted drug delivery to the cardiovascular system, in particular, is seen to hold much promise with several main advantages. This approach enables a more precise and effective delivery of therapeutic drugs directly to the heart and blood vessels, enhancing treatment outcomes while minimizing undesirable side effects. However, at the same time, there remains several impediments that have to be addressed to realize the formulation of effective systems for the delivery of drugs to the cardiovascular system. Work actively ongoing in Cardiovascular Drug Delivery Specialty Section aims to do these in order to help these new approaches enter the clinics. These efforts aim to ultimately reduce the global burden of cardiovascular diseases. Also, there is a need to conduct additional research for the improvement of the design and structure of drug delivery systems as well as the external factors applied in the control of drug delivery within the body so that the therapies would be maximally efficient and safe with few undesirable effects.